静脉血栓新药拜瑞妥多少钱？

(Rivaroxaban) is a highly selective, oral drug that directly inhibits factor Xa. It was first launched in Canada in September 2008, and was approved by the European Union in October. It was launched in the United States by Johnson & Johnson in July 2001. In June 2009, Xarelto was officially launched in China. Today we will learn more about the new drug Xarelto for venous thrombosis. How much does it cost?

According to Medical Companion Travel, Xarelto 10mgx28 tablets is about 170, 15mgx28 tablets is about 500$, and 20mgx28 tablets is about 500$. Since exchange rates fluctuate and prices are not fixed, please consult Medical Travel for specific prices. Patients in need can purchase Xarelto (rivaroxaban) at major domestic pharmacies or obtain Xarelto (rivaroxaban) through domestic professional overseas medical service institutions (such as Medical Travel) to ensure that the drug is genuine.

Xarelto (rivaroxaban) was approved by the State Food and Drug Administration for marketing in China in 2009. In the same year, Xarelto was also included in the national medical insurance catalog, which relieved a certain burden on the treatment of many domestic patients. Patients can purchase it at regular domestic hospital pharmacies, but the financial burden of long-term use is still relatively heavy.

Dosage and usage of Xarelto (rivaroxaban): The recommended dose is 10 mg of Xarelto taken orally, once daily. If the wound has stopped bleeding, the medication should be administered between 6-10 hours after surgery. The length of treatment is determined by each patient's risk of VTE, i.e. by the type of orthopedic surgery the patient has undergone.

For patients undergoing major hip surgery, a recommended course of treatment is 5 weeks. For patients undergoing major knee surgery, a recommended course of treatment is 2 weeks. If a missed dose occurs, the patient should take Xarelto (rivaroxaban) immediately and continue taking the drug once a day the next day. Patients can take Xarelto with a meal or alone.

Xarelto (rivaroxaban) is clinically indicated for the prevention of venous thrombosis (VTE) in adult patients undergoing elective hip or knee replacement surgery. Its main mechanism of action is: inhibitory factor Xa can interrupt the endogenous and exogenous pathways of the coagulation cascade and inhibit the generation of thrombin and thrombosis. A dose-dependent inhibition of factor Xa activity by Xarelto has been observed in humans. Clinical studies have shown that Xarelto can effectively prevent deep vein thrombosis after postoperative fractures around the hip joint. It has good safety and is worthy of clinical promotion.

The above is the price content of (Rivaroxaban), I hope it can help you!

Recommended related hot articles: /newsDetail/76631.html